Sign in
Taking people in South KoreaNo phase

Watching safety of durvalumab with or without olaparib in endometrial cancer patients

Studies durvalumab, alone or with olaparib, in endometrial cancer patients receiving routine care.

Key facts

Who runs it
AstraZeneca
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Status
Recruiting
People taking part
50 people, planned
Started
19 Sept 2025
Expected to end
29 Jun 2029
Type of study
Observational
Record updated
2 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people in Korea with endometrial cancer who are prescribed Durvalumab, with or without Olaparib, under its approved use. It watches safety and effectiveness in routine care.

Sex
All sexes can join.
Disease stage
Endometrial cancer treated under the approved use of the study drug in Korea.

Main reasons for not taking part

  • Taking part in another interventional trial during the study drug treatment
  • Use of the study drug for an off-label indication, not in the approved label in Korea

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Patients eligible for the study drug according to the approved label in Korea
  • Provision of a signed and dated written informed consent by the patient or their legally acceptable representative

Who cannot take part

  • Participation in any concurrent interventional trials during the period of the study drug treatment
  • Other off-label indications according to the approved label in Korea

Where in South Korea

  • SeoulHospital not named in the registryTaking people

About the trial

What the trial wants to find out

Objectives of this study are to assess the safety and effectiveness of Durvalumab with or without Olaparib (hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug under the approved indication in Korea.

Read full original descriptionShow less

This is a multicenter, prospective, observational, real world treatment study. Patients treated as part of routine practice at Korean healthcare centers by investigators will be identified and considered for inclusion in the study. The period of this study is expected to run for 4 years from the approval date of the indication for this study. Approximately 50 patients are expected to be enrolled during the study.

Patient will be followed for approximately 12 months from the first dose or up to 90 days after treatment discontinuation if the study drug is administered for less than 12 months, unless they withdraw consent, are lost to follow-up or death.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Plain-language title
Watching safety of durvalumab with or without olaparib in endometrial cancer patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 September 2026